PERVALUE CAPITAL’s Post

𝗠𝗮𝗿𝗸 𝗖𝘂𝗯𝗮𝗻 𝗶𝘀 𝗱𝗶𝘀𝗿𝘂𝗽𝘁𝗶𝗻𝗴 𝘆𝗲𝘁 𝗮𝗻𝗼𝘁𝗵𝗲𝗿 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆, 𝗮𝗻𝗱 𝘁𝗵𝗶𝘀 𝘁𝗶𝗺𝗲, 𝗶𝘁 𝗰𝗼𝘂𝗹𝗱 𝘀𝗮𝘃𝗲 𝗹𝗶𝘃𝗲𝘀! After his remarkable journey as a tech entrepreneur, Cuban has shifted gears with a bold mission: 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺 𝘁𝗵𝗲 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆. Imagine a world where life-saving medications are priced transparently, with no hidden fees or inflated costs. In this fascinating interview, Cuban shares his journey from receiving a cold email in 2018 to launching a pharmaceutical company that offers over 2,500 generic drugs. 𝗛𝗶𝘀 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝗶𝘀: 𝗯𝗮𝘀𝗲 𝗽𝗿𝗶𝗰𝗲 + 𝟭𝟱% 𝗺𝗮𝗿𝗸𝘂𝗽 + $𝟱 𝗳𝗼𝗿 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝘆 𝘀𝗲𝗿𝘃𝗶𝗰𝗲𝘀 + $𝟱 𝗳𝗼𝗿 𝘀𝗵𝗶𝗽𝗽𝗶𝗻𝗴. Simple, fair, and potentially life-saving. Families who can now afford essential medications. Patients who no longer have to choose between healthcare and their livelihood. #innovation #entrepreneurship #leadership

#ICYMI Discussing our key themes from #ScaleUpHealth2024, Prem Pavoor (Eight Roads), spent time with Ekta Batra and Mangalam Maloo on CNBC-TV18's Half Time Report. If you missed coming along to the event, watch this interesting conversation about the growing potential of anti-obesity drugs, the #CDMO opportunity and much more. Watch the full interview here - https://lnkd.in/g9GBHt2v #healthcare #healthcareinnovation #pharmaceuticals #lifesciences #scaleup #scaleuphealth #startups #founders #trends

#TBT: Check out this feature from the Longhorn Network Game Changers series in 2015. Nearly 10 years later, this work has only evolved through the Innovating for Health Institute! . #innovation #drugdevelopment #pharmaceutical #pharma #entrepreneurship #utexas #longhornnetwork

Activist investor Starboard Value has acquired a $1 billion stake in Pfizer. They are pushing for strategic changes to improve the company’s performance, which has struggled post-pandemic with declining sales and competition. Starboard has also approached former Pfizer executives Ian Read and Frank D’Amelio to assist in their efforts. What are your thoughts on this move by Starboard Value?

💊Over the past five years, an average of 50 new drugs per year have secured FDA approval. However, where an increasing number of drugs vie for a slice of the national healthcare budget, projected peak sales are simultaneously declining. Is the health innovation industry falling victim to its own growing success? Find out in our new article! https://lnkd.in/e3wsBFBm V-Bio Ventures

Proud to have fellow Biotechnology Innovation Organization board member and Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) CEO Frank Watanabe testify at the House Ways and Means Committee hearing on July 12th in Salt Lake City. Frank highlighted the contributions the biotech industry has made to human health and the economy: "In the last quarter century, American life expectancy has continued its steady increase upwards, with roughly one-third of that improvement directly attributable to biopharmaceutical innovations.” The big picture: The industry’s direct and indirect contribution to the U.S. GDP is anywhere from 2-7%, with an economic impact of $2.9 trillion in 2021. Biotech capabilities enhance national security by ensuring we can care for ourselves. Legislative proposals that would support innovation include: - The Ensuring Pathways to Innovative Cures (EPIC) Act, which would give small molecule drugs the same 13-year protection from price controls as biologics, and the ORPHAN Cures Act, which would exempt orphan drugs from price controls even if approved for more than one indication. - The Tax Relief for American Families and Workers Act (H.R. 7024), which was passed by the House earlier this year, to restore the R&D tax deduction. Allow for monetization of net operating losses (NOLs) and reform Section 382 on NOLs. - Improve the capital gains exemption under Section 1202 to encourage investment in small biotechs. - Ensure strong strong patent protections and reasonable regulation of M&A activity. Proud of the work BIO does to support the industry, and proud to be a part of community that works tirelessly to drive innovation and improve human and planetary health. #patientsfirst #biotechnology #innovation #humanhealth #sustainability

Stories making headlines today in the biopharma industry: US Intelligence officials recently informed Congress WuXi AppTec allegedly transferred a US client's intellectual property to Chinese authorities without approval, rousing concerns about the activities of WuXi and other Chinese firms. This unfolds prior to the Senate's vote on the BIOSECURE Act, potentially curtailing the activities of Chinese healthcare companies in the US. Simultaneously, WuXi AppTec and WuXi Biologics declare ongoing expansion of US operations amidst increasing political pressure. They've faced criticism following the BIOSECURE Act proposal, which would prevent federally funded companies from associating with firms connected to 'foreign adversaries,' including WuXi. Senator Bernie Sanders has urged pharmaceutical firm Novo Nordisk to lower the prices of drugs Ozempic and Wegovy significantly, citing vast price disparities compared to other global regions like Canada. In other news, Nestlé Health Science is outlining future steps for its C. diff drug, Vowst, following successful uptake since launch. The drug's triumph is credited to increasing doctor awareness regarding microbiome function, supported by Nestlé's specialized sales team. Walgreens reported a $5.9 billion net loss in its quarterly financial results, primarily attributed to a $5.8 billion impairment charge on its investment in primary care chain VillageMD. CEO Tim Wentworth announced the intent to close 160 clinics as part of cost-saving operations. A judge in New Jersey has given Johnson & Johnson the opportunity to challenge evidence from plaintiffs amidst ongoing talc litigation. J&J believes it is time to reevaluate plaintiff evidence due to relevant scientific developments and changes to the governing federal rule for expert testimony. Lastly, biotech firm Genentech aims to increase clinical trial diversity, labeling it as a 'business imperative'. The company announced the provision of resources and training to sites to enhance diversity and inclusivity in clinical trials, along with education to clinical trial designers for the removal of barriers to trials faced by diverse populations. #pharma #biotech #topstories #biodatastudio

New: Former Novartis CEO Joe Jimenez and the pharma's long-time research leader Mark Fishman are targeting $400 million for their third fund at Aditum Bio. The Oakland, CA-based firm in-licenses drugs, sets up a company around them and takes the experimental medicines through clinical development toward an M&A exit, like it has done with Versanis Bio, bought by Eli Lilly for up to $1.9 billion last year. Aditum has created 10 companies so far. “I was very clear with all of my investors that out of the 10 companies, I expect only three of them to provide good data, and seven of them will shut down,” Jimenez said in an interview with Endpoints News last fall. “Many times in pharma, if you’re in Phase 2 and you don’t get a positive readout, there’s a project team that’s willing to convince management that all they have to do is change the patient population, and they’re going to have success. That’s not what we’re about.” #biotech #vc #lifesciences #venturecapital #drugdevelopment

*Bitter truth * "*Is curing patients a sustainable business model*?" *Curing Patients Is Bad for Business*: Pharmaceutical companies are developing new drugs in only two therapeutic areas these days -- cancer and rare diseases. Why? These are the only therapeutic areas where exorbitant pricing is tolerated by payers. if you develop a new drug that cures people rapidly, then patients will not need to take the drug on an ongoing basis, and that limits the amount of money a company can make. Since the neo-liberal revolution of the 1980s pharmaceutical companies have super charged their profiteering, at the expense of patients. Regardless of whether the underlying medicines were actually produced or not, the intellectual property was an incredibly profitable commodity in its own right, open to being moved around to hide profits or avoid regulation, or bought and sold on financial markets. If Banks help you get out of Debt, they would fail If politicians solves all your problems, nobody will reelect them